Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Relapsed CLL responds to rapid venetoclax dose-escalation

Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357

Key clinical point: CLL relapsed after therapy with a B-cell receptor signaling inhibitor has a rapidly progressive course, requiring quick ramp up of venetoclax.

Major finding: All patients reached the target dose of venetoclax, with only two cases of manageable clinical tumor lysis syndrome.

Study details: Retrospective analysis of outcomes for 15 patients with chronic lymphocytic leukemia relapsed after treatment with a B-cell receptor signaling inhibitor.

Disclosures: The study was internally funded. Dr. Awan receives research funding from Gilead, Pharmacyclics. AbbVie and Janssen.

Source: Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357

Citation:

Awan F et al. European Hematology Association 2018 Annual Congress. Abstract PF357

This Week's Must Reads

Gene sequencing bone marrow in myelodysplastic syndrome, Duncavage EJ et al. N Engl J Med 2018;379:1028-41.

Levofloxacin prophylaxis in ALL, AML , Alexander S, et al. JAMA. 2018;320(10):995-1004

Genetic markers signal poor prognosis in MCL, Obr A et al. Clin Lymphoma Myeloma Leuk. 2018 Aug 23. doi: 10.1016/j.clml.2018.07.282

Disparities in ALL treatment toxicity, Taylor OA et al. Clin Cancer Res. 2018 Sep 11. doi: 10.1158/1078-0432.CCR-18-0939

Leukemia risk after maternal contraception use, Hargreave M et al. Lancet Oncol. 2018 Sep 6. doi: 10.1016/S1470-2045(18)30479-0

Must Reads in CLL

First-line ibrutinib has long-term survival benefit, Barr PM et al. Haematologica. 2018;103(9):1502-10.

Obinutuzumab plus venetoclax compares well with established CLL therapies, Cramer P et al. Lancet Oncol. 2018 Aug 13. doi: 10.1016/S1470-2045(18)30414-5.

Caution urged over real-world bleeding risk with ibrutinib, Kunk PR et al. Clin Lymphoma Myeloma Leuk. 2018 Jul 15. doi: 10.1016/j.clml.2018.07.287

New guidelines from the UK on chronic lymphocytic leukemia, Schuh AH et al. Br J Haematol. 2018 Jul 15. doi: 10.1111/bjh.15460

Escalating venetoclax dose was safe in relapsed CLL, Koenig K et al. EHA Congress (annual meeting of the European Hematology Association), Abstract PF357.